Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock
April 08 2019 - 4:28PM
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health
innovation, today announced that it intends to offer shares of its
common stock in an underwritten public offering. Daré expects
to grant to the underwriters of the offering a 30-day option to
purchase up to an additional 15% of the shares of common stock
offered in the underwritten public offering on the same terms and
conditions. The offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the
offering.
Roth Capital Partners is acting as the sole book-runner for the
offering. Aegis Capital Corp. is acting as co-manager for the
offering.
The Company intends to use the net proceeds from the offering
for working capital and general corporate purposes, including to
advance its product candidate portfolio and general and
administrative expenses.
A shelf registration statement relating to the shares of common
stock to be issued in the proposed offering was filed with the
Securities and Exchange Commission (the "SEC") and is effective.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Copies of the
preliminary prospectus supplement and accompanying prospectus will
be filed with the Securities and Exchange Commission and, when
available, may be obtained from Roth Capital Partners, LLC, 888 San
Clemente, Suite 400, Newport Beach, CA 92660, (800) 678-9147 or by
accessing the SEC's website, www.sec.gov.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company
committed to the advancement of innovative products for women’s
health. The company’s mission is to identify, develop and bring to
market a diverse portfolio of differentiated therapies that expand
treatment options, improve outcomes and facilitate convenience for
women, primarily in the areas of contraception, vaginal health,
sexual health, and fertility.
Daré’s product portfolio includes potential first-in-class
candidates in clinical development: Ovaprene®, a non-hormonal,
monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a
novel cream formulation of sildenafil to treat female sexual
arousal disorder utilizing the active ingredient in Viagra®;
DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2%
to treat bacterial vaginosis via a single application; and
DARE-HRT1, a combination bio-identical estradiol and progesterone
intravaginal ring for hormone replacement therapy following
menopause. To learn more about Daré’s full portfolio of women’s
health product candidates, and mission to deliver differentiated
therapies for women, please visit www.darebioscience.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of The Private Securities Litigation Reform Act of 1995
regarding matters that are not historical facts, including
statements relating to Daré's expectations regarding the completion
and terms of the proposed public offering including and the
company’s proposed use of proceeds. Forward-looking statements are
subject to known and unknown risks and uncertainties, many of which
may be beyond our control. We caution you that the forward-looking
information presented in this press release is not a guarantee of
future events, and that actual events may differ materially from
those made in or suggested by the forward-looking information
contained in this press release. In addition, any forward-looking
statements included in this press release represent our views only
as of the date of this release and should not be relied upon as
representing our views as of any subsequent date. Daré specifically
disclaims any obligation to update any forward-looking statements
included in this press release.
Contacts:
Investors on behalf of Daré Bioscience, Inc.: Alex
GrayBurns McClellanagray@burnsmc.com212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.Amanda GuisbondCanale
Communicationsamanda@canalecomm.com781-405-8775
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024